Your goal is ApoB / LDL-P. Zero human studies measured ApoB [6]. The best trial (3-year RCT) was flatly null on plaque [1], and a 2024 meta-analysis found nattokinase nudged LDL-C the wrong way (+6.49 mg/dL) [3].
The only reproducible effect is mild blood-thinning (clot-marker shifts) [4]. That is exactly where your EPA fish oil + quercetin already stack antiplatelet effect, and you drink. Real added bleeding risk, no proven payoff for you [5].
The "natural statin melts plaque" story is manufacturer-funded and did not survive verification [1].
| Endpoint | Signal | Best evidence (real numbers) |
|---|---|---|
| Plaque / atherosclerosis | No effect | NAPS RCT (Hodis 2021, double-blind, n=265, 2,000 FU/day, median 3 yr): carotid IMT progression 0.013 vs 0.011 mm/yr, p=0.31 = null. The big positive results (Chen 2022: plaque -36% at 10,800 FU/day; Ren 2017) are retrospective or small single-center studies with manufacturer-employed authors. The "beat simvastatin" claim was refuted 0-3. [1] |
| Blood pressure | Weak / mixed | One small 8-wk RCT (Kim 2008, n=73 completed, 2,000 FU/day) showed SBP -5.55 mmHg (95% CI -10.5 to -0.57) and DBP -2.84 mmHg. But the larger 3-yr NAPS RCT found no BP effect, and a claimed 6-RCT meta-analysis BP benefit was refuted 0-3. [2] |
| Lipids / ApoB | None / adverse | 2024 RCT meta-analysis: low-dose nattokinase raised LDL-C +6.49 mg/dL (p=0.02) and total cholesterol +5.27, lowered HDL -2.76. The one LDL drop in a trial (-0.537 mmol/L) came from co-dosed red yeast rice (9.0 mg monacolin K = lovastatin), not nattokinase. No study measured ApoB. [3] |
| Clot markers (fibrinolysis) | Real, but soft | Kurosawa 2015 (n=12, single 2,000 FU): D-dimer +44.5% at 6h, fibrin-degradation products +21.2% at 4h. Hsia 2009 (n=45, 4,000 FU/day, 2 mo): fibrinogen -7 to -10%, factor VII -7 to -14%, factor VIII -17 to -19%. Caveat: shifts stayed within normal range; no hard clinical outcomes (no heart-attack / stroke / event data). [4] |
Controlled trials cluster at 2,000 to 4,000 FU/day (FU = fibrinolytic units, the active measure), taken as a single morning dose; fibrinolytic markers peak 4 to 8 hours later [4][7]. The flat claim that "2,000 FU/day is the validated effective dose" was refuted 0-3, precisely because the highest-quality 2,000 FU/day trial was null on outcomes [7]. Translation: there is no dose with clean proof of a hard benefit.
The label-appropriate pick is Doctor's Best Nattokinase, 2,000 FU, 90 veg caps: it states FU potency and is processed with vitamin K2 removed (the right call since you already get K2 from your D3+K2). Nutricost Nattokinase 2,000 FU (120 caps) is a cheaper equivalent. [8]
Honesty flag: these are label claims from retail listings, not third-party verified. I could not confirm an NSF- or USP-tested nattokinase from independent assay. Nattokinase potency (FU) is notoriously inconsistent between brands, so a "2,000 FU" label is a claim, not a guarantee. [8]
For your specific mission, this is a pass. It does not lower ApoB or LDL particles (the thing you are actually fighting), the best trial shows no plaque benefit, and the only reliable effect is mild blood-thinning that compounds risk with your fish-oil + quercetin + alcohol mix without a proven outcome. If you still want the fibrinolytic angle, treat it as a low-conviction experiment, K2-removed, ~2,000 FU each morning, with the bleeding caution above and a heads-up to your lab doctor. Your existing lipid-lever stack (Omega-3, CholestOff, RYR, berberine, bergamot) is doing far more for your actual numbers than nattokinase would.